Discovery & Development

Incyte's drug discovery efforts were founded in 2002 by a team of world-class scientists striving to create innovative medicines for patients. The rigorous pursuit of scientific excellence remains at the core of our company today.

Our discovery approach integrates target selection, portfolio "fit," compound quality, and pharmacodynamic optimization. This approach ensures we not only develop molecules with characteristics optimized for their intended use but also build a portfolio that is strategically coherent and synergy-rich.

PORTFOLIO

Focused on transforming the treatment of cancer and other conditions with innovative new therapies.
Learn More

IMMUNOTHERAPY DISCOVERY

Incyte's discovery strategy within the field of immunotherapy is based on the diversity of cells required to maintain an immune-suppressive microenvironment. Immune subversion by cancer cells is mediated by the action of multiple immune-regulatory cell types, and Incyte's discovery capabilities based on both small and large molecule modalities open distinct opportunities to target diverse mechanisms, including: JAK, PI3Kδ, PD-1, IDO1, OX40, and GITR.

Click here to see our Immunotherapy Discovery visual

 

TARGETED THERAPY DISCOVERY

Incyte's targeted therapy discovery strategy emphasizes the prosecution of therapeutic intervention points that lie in interdependent oncogenic pathways. This enables us to readily leverage cross-program knowledge throughout the research and development continuum as well as identify and exploit novel points of synergy.

Click here to see our Targeted Therapy Discovery visual